ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
18.16
-0.24 (-1.30%)
At close: Jun 27, 2025, 4:00 PM
18.06
-0.10 (-0.55%)
After-hours: Jun 27, 2025, 7:56 PM EDT
ADMA Biologics Revenue
ADMA Biologics had revenue of $114.80M in the quarter ending March 31, 2025, with 40.22% growth. This brings the company's revenue in the last twelve months to $459.38M, up 62.22% year-over-year. In the year 2024, ADMA Biologics had annual revenue of $426.45M with 65.15% growth.
Revenue (ttm)
$459.38M
Revenue Growth
+62.22%
P/S Ratio
9.30
Revenue / Employee
$670,629
Employees
685
Market Cap
4.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 426.45M | 168.24M | 65.15% |
Dec 31, 2023 | 258.22M | 104.13M | 67.59% |
Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADMA News
- 12 days ago - ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade) - Seeking Alpha
- 7 weeks ago - ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss - Seeking Alpha
- 7 weeks ago - ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 2 months ago - ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process - GlobeNewsWire
- 2 months ago - ADMA Biologics Statement on Tariffs - GlobeNewsWire
- 3 months ago - ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential - Seeking Alpha